The Latest Cardiac and Vascular News
FEops HEARTguide significantly improves efficiency and outcomes of LAAO procedures in the PREDICT-LAA Randomized Clinical Trial GENT, Belgium–(BUSINESS WIRE)–Data from the PREDICT-LAA trial, presented at the Late-Breaking Innovation session at the TCT 2022 convention in Boston shows that Left Atrial Appendage occlusion (LAAO) procedures planned by means of FEops HEARTguideTM result […]
BOSTON–(BUSINESS WIRE)–Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking […]
FDA Also Approves and Closes RECOVER III Post-Approval Study DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients. The FDA has approved the on-label RECOVER IV randomized controlled […]
Interim data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 showed deep and sustained mean serum transthyretin (TTR) reductions of 93% and 92% at 0.7 mg/kg and 1.0 mg/kg doses, respectively, at day 28 NTLA-2001 was generally well-tolerated at both dose levels Intellia to discuss data at […]
Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures Philips Engagement Hub at TCT to feature a range of physician-led discussions, in-depth symposia, and hands-on trainings that address some of today’s most pressing cardiology challenges Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), […]
DUBLIN, Sept. 15, 2022 /PRNewswire/ — Medtronic plc (the “Company”) ( NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. (“Medtronic Luxco”), has priced an offering (the “Offering”) of €500,000,000 principal amount of 2.625% senior notes due 2025, €1,000,000,000 principal amount of 3.000% senior notes due 2028, €1,000,000,000 principal amount of […]
New Heart Valve Durability tester with Automatic Dual Control technology debuts at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation. “Introducing a New Generation of Durability Testers” VICTORIA, BC, Sept. 16, 2022 /PRNewswire/ — ViVitro Labs, the industry-leading provider of cardiovascular device test equipment and related […]
Three leading U.S. interventional cardiologists attend initial cases as company prepares to expand its clinical program LOS GATOS, Calif., Sept. 16, 2022 /PRNewswire/ — Supira Medical, Inc., a Shifamed portfolio company focused on developing the next-generation solution for mechanical circulatory support, announced today it has initiated its first-in-human clinical study performed by principal […]
Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels ANN ARBOR, Mich.–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first […]
Merger unites three companies created by life sciences venture capital firm ATP—Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics—to create a single company based on the AliyaTM Pulsed Electric Field (PEF) energy platform Galvanize is developing and commercializing systems for chronic bronchitis symptoms, cardiac arrhythmias, solid tumors, and drug delivery $100 million funding […]
